🔗 Permalink

Inventor profile of:

Allergan, Inc.

City:

Country:

United States

Published Applications:

Last publication date:

2014-02-27

Top Assignees for applications by Allergan, Inc.

The entities that hold a legal rights for patent applications filed by inventor Allergan, Inc.:

Allergan, Inc. 21 Irvine, CA United States
Allergen, Inc. 1 Irvine, CA United States

Recent patent applications by Allergan, Inc.

Allergan, Inc. from , US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2014-02-27

US20140058313A1

Human necessities

Methods and devices for desmopressin drug delivery

#2 | 2013-12-12

US20130330321A1

Chemistry; metallurgy

Injection paradigm for administration of botulinum toxins

#3 | 2013-08-29

US20130225505A1

Chemistry; metallurgy

MUTEINS OF HUMAN TEAR LIPCALIN FOR TREATING NEOVASCULAR DISEASE OF THE ANTERIOR SEGMENT OF THE HUMAN EYE

#4 | 2013-08-29

US20130224180A1

Human necessities

Injection paradigm for administration of botulinum toxins

#5 | 2013-08-29

US20130224178A1

Human necessities

Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopepidases

#6 | 2013-08-22

US20130217739A1

Chemistry; metallurgy

Therapeutic compounds

#7 | 2013-08-22

US20130217720A1

Chemistry; metallurgy

Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators

#8 | 2013-08-22

US20130217694A1

Human necessities

METHOD OF REDUCING THE SEVERITY OF INFLAMMATORY DERMATOLOGICAL CONDITIONS

#9 | 2013-08-22

US20130217667A1

Chemistry; metallurgy

Phenoxy-azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators

#10 | 2013-08-22

US20130217652A1

Chemistry; metallurgy

SULFINYLBENZYL AND THIOBENZYL DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS

#11 | 2013-08-22

US20130217651A1

Chemistry; metallurgy

Phenoxy derivatives as sphingosine 1-phosphate (S1P) receptor modulators

#12 | 2013-08-22

US20130217650A1

Chemistry; metallurgy

Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors

#13 | 2013-08-22

US20130217129A1

Chemistry; metallurgy

CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE

#14 | 2013-08-22

US20130217069A1

Chemistry; metallurgy

CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE

#15 | 2013-08-15

US20130210876A1

Human necessities

ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OF INTRAOCULAR PRESSURE-LOWERING EFFECT

#16 | 2013-08-15

US20130210862A1

Human necessities

Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

#17 | 2013-08-15

US20130210725A1

Human necessities

CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE

#18 | 2013-08-15

US20130210076A1

Chemistry; metallurgy

CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE

#19 | 2013-08-15

US20130209661A1

Human necessities

Processes for making porous implantable materials

#20 | 2013-08-15

US20130209532A1

Human necessities

Polysaccharide gel formulation having increased longevity

#21 | 2013-08-15

US20130209398A1

Human necessities

Conditioned cell culture medium compositions and methods of use

InventorID:

388320 ⎘